A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants with Alzheimer’s Disease
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, BIOMARKERS, AND EFFICACY OF TOMINERSEN IN INDIVIDUALS WITH PRODROMAL AND EARLY MANIFEST HUNTINGTON’S DISEASE
A Multicenter Longitudinal Study to Evaluate the Correlation between Oculometric Measures and Clinical Assessment in Patients with Idiopathic Parkinson's Disease (PALOMA trial)
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type
A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants with Huntington’s Disease
A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants with Alzheimer’s Disease
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
Real-world performance evaluation of PreSize Neurovascular medical software in a clinical setting
EEG based Awareness Detection and Communication in Prolonged Disorders of Consciousness and Physical Disability
MND Register for England, Wales and Northern Ireland
EEG based Awareness Detection and Communication in Prolonged Disorders of Consciousness and Physical Disability
Developing a fatigue treatment for multiple sclerosis (MS): exploring the views of people living with MS, people providing care or assistance to those living with MS, and healthcare professionals
Developing a fatigue treatment for multiple sclerosis (MS): exploring the views of people living with MS, people providing care or assistance to those living with MS, and healthcare professionals
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
NIHR Mental Health BioResource for Depression and Anxiety
Systemic inflammation and the blood-brain barrier in multiple sclerosis.
Neurological Long-term Conditions: Online Integrated Care Platform Study
OptiCALS: A Randomised Controlled Trial with parallel Process Evaluation and Health Economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with Amyotrophic Lateral Sclerosis
OptiCALS: A Randomised Controlled Trial with parallel Process Evaluation and Health Economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with Amyotrophic Lateral Sclerosis
MND Register for England, Wales and Northern Ireland
EEG based Awareness Detection and Communication in Prolonged Disorders of Consciousness and Physical Disability
NIHR Mental Health BioResource for Depression and Anxiety
Systemic inflammation and the blood-brain barrier in multiple sclerosis.
NIHR Mental Health BioResource for Depression and Anxiety
Systemic inflammation and the blood-brain barrier in multiple sclerosis.
EEG based Awareness Detection and Communication in Prolonged Disorders of Consciousness and Physical Disability
NIHR Mental Health BioResource for Depression and Anxiety
Systemic inflammation and the blood-brain barrier in multiple sclerosis.
MND Register for England, Wales and Northern Ireland
NIHR Mental Health BioResource for Depression and Anxiety
OptiCALS: A Randomised Controlled Trial with parallel Process Evaluation and Health Economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with Amyotrophic Lateral Sclerosis
EEG based Awareness Detection and Communication in Prolonged Disorders of Consciousness and Physical Disability
MND Register for England, Wales and Northern Ireland
OptiCALS: A Randomised Controlled Trial with parallel Process Evaluation and Health Economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with Amyotrophic Lateral Sclerosis
EEG based Awareness Detection and Communication in Prolonged Disorders of Consciousness and Physical Disability
NIHR Mental Health BioResource for Depression and Anxiety
OptiCALS: A Randomised Controlled Trial with parallel Process Evaluation and Health Economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with Amyotrophic Lateral Sclerosis
EEG based Awareness Detection and Communication in Prolonged Disorders of Consciousness and Physical Disability
MND Register for England, Wales and Northern Ireland
MND Register for England, Wales and Northern Ireland
NIHR Mental Health BioResource for Depression and Anxiety
NIHR Mental Health BioResource for Depression and Anxiety
MND Register for England, Wales and Northern Ireland
NIHR Mental Health BioResource for Depression and Anxiety
OptiCALS: A Randomised Controlled Trial with parallel Process Evaluation and Health Economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with Amyotrophic Lateral Sclerosis